Better Than Bitcoin? (Top Crypto for Less Than $1)

Over the past 15 years, Bitcoin has outperformed stocks, bonds, and every other asset you could've bought. 2025 is already shaping up to be another banner year, with Bitcoin recently hitting a new all-time high. But there's a better way to profit from this new crypto rally. Most people don't know about it... and yet it's returned over 1,000% in 4 months. This could be the #1 way to invest in crypto right now.

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

Vandana Singh
July 21, 2025

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1).

Narcolepsy is a chronic neurological disorder that disrupts the body’s ability to regulate sleep-wake cycles. It’s characterized by excessive daytime sleepiness and sudden, uncontrollable sleep attacks.

Alixorexton, formerly ALKS 2680, is an investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for NT1, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

Also Read: Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

In Vibrance-1, alixorexton met the primary endpoint across all doses tested, demonstrating statistically significant, clinically meaningful, and dose-dependent improvements in wakefulness on the Maintenance of Wakefulness Test (MWT) from baseline compared to placebo.

In addition to achieving normative wakefulness across all dose groups on the MWT (mean sleep latency >20 minutes), once-daily alixorexton demonstrated robust and clinically meaningful improvements compared to placebo on patient-reported outcomes related to excessive daytime sleepiness and other key symptoms such as fatigue and cognition.

Alixorexton was generally well tolerated at all doses tested. These data support rapid initiation of a global phase 3 program of alixorexton in patients with NT1.

Key Secondary Endpoints

Epworth Sleepiness Scale (ESS): At all doses tested, alixorexton drove statistically significant and clinically meaningful improvements from baseline in excessive daytime sleepiness compared to placebo on the Epworth Sleepiness Scale at week six (p<0.0001 at all doses).

Weekly Cataplexy Rates (WCR): Alixorexton numerically improved weekly cataplexy rates across all doses compared to placebo at week six and achieved statistical significance at the 6 mg dose (p=0.005).

Alixorexton demonstrated consistent and clinically meaningful improvements across several patient-reported outcome measures of symptoms important to patients, including:

Narcolepsy Severity Scale (NSS): Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in narcolepsy symptom severity as compared to placebo at week six (p<0.001 at all doses).

British Columbia Cognitive Complaints Inventory (BC-CCI): Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in cognitive complaints compared to placebo at week six (p<0.0001 at all doses).

PROMIS (Patient-Reported Outcomes Measurement Information System)-Fatigue: Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in fatigue as compared to placebo at week six (p<0.01 at all doses).

Alixorexton was generally well tolerated across all doses tested in the randomized double-blind period of the Vibrance-1 study.

No treatment-emergent serious adverse events (TEAEs) were reported. Most TEAEs were mild to moderate in severity and generally consistent with the events observed across the Alixorexton phase 1 program in healthy volunteers and patients.

No treatment-related safety signals were observed in hepatic and renal parameters, vital signs, or ophthalmic exams.

Vibrance-2 and Vibrance-3, phase 2 studies evaluating the safety and efficacy of alixorexton in adults with NT2 and IH, respectively, are ongoing.

In April 2024, Alkermes revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for narcolepsy

ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test compared to placebo at all doses tested. 

Price Action: ALKS stock is trading lower by 7.24% to $27.11 at last check Monday.

Read Next:

  • China-Led Rally Sends Iron Ore Over $100 Despite Looming Oversupply

Photo via Shutterstock

Continue Reading...

Popular

Paula Deen has abruptly closed the Savannah restaurant that launched her to Food Network fame

SAVANNAH, Ga. (AP) — Former Food Network star Paula Deen announced Friday the abrupt closure of the Savannah restaurant that launched her to fame with its menu of fried chicken, banana pudding and other indulgent Southern dishes.

These 3 Dividend-Yielding Stocks Could Outperform As High Fed Rates Spark $4.9 Billion Inflows: Expert

Expert highlights the top high divided yielding stocks and funds that investors could consider to seize the opportunity amid high Fed rates.

Gold Is Being Reintroduced Into the Monetary System - Ad

While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.

Wallis Annenberg, billionaire philanthropist who backed arts, science and other causes, dies at 86

LOS ANGELES (AP) — Wallis Annenberg, the billionaire philanthropist who supported the arts, science, education and animal welfare causes over decades in Los Angeles, died Monday, her family said.

No.1 Opportunity for 2025 [Take Action Now!] - Ad

Starlink's potential IPO Could Be the Biggest in History--Silicon Valley insider James Altucher has uncovered a way to profit BEFORE the IPO--with as little as $50. Musk's $180B giant is set to launch--will you miss out? Claim your spot before it's too late.

How high-tech tools, and pigs, could help in the search for Mexican drug cartel victims

ZAPOPAN, Mexico (AP) — First the scientists dress dead swine in clothes, then they dispose of the carcasses. Some they wrap in packing tape, others they chop up. They stuff the animals into plastic bags or wrap them in blankets. They cover them in lime or burn them. Some are buried alone, others in groups.

It’s moo-ving day for dairy cattle at Michigan State University

EAST LANSING, Mich. (AP) — Dozens of dairy cattle were on the moo-ve Monday at Michigan State University.

Trump: Don't Mess With This American Stock! - Ad

One little-known U.S. stock is 20x cheaper than AMD--yet more profitable than Airbnb, Chipotle, and Hilton. Backed by Trump and now partnering with a top AI firm, it's poised to explode.

Jury orders Tesla to pay more than $200 million in Autopilot crash case

MIAMI (AP) — A Miami jury decided that Elon Musk’s car company Tesla was partly responsible for a deadly crash in Florida involving its Autopilot driver assist technology and must pay the victims more than $200 million in punitive damages.

The Tea app was intended to help women date safely. Then it got hacked

Tea, a provocative designed to let women anonymously ask or warn each other about men they'd encountered, rocketed to the top spot on the U.S. Apple App Store this week. On Friday, the company behind the app confirmed : Thousands of images, including selfies, were leaked online.

The Surprising New Date That Could Fuel the AI Boom - Ad

Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.

UK transport secretary demands answers from air traffic control chief after flight disruption

LONDON (AP) — Britain’s transport chief has summoned the head of the country’s air traffic control operator to explain the problem that grounded and diverted dozens of flights Wednesday.

Ranchers say expanding herds to take advantage of record retail beef prices isn't so simple

MINNEAPOLIS (AP) — In a period when retail beef prices are at an all-time high and consumers are still willing to pay, South Dakota rancher Calli Williams would love to cash in. But it's not so simple.

Is Elon's Empire Crumbling? - Ad

Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after October 23rd, it may be too late.

A US judge says arrested Haitian businessman and former presidential hopeful will remain in custody

SAN JUAN, Puerto Rico (AP) — A federal immigration judge in Miami ordered on Thursday that wealthy remain in custody in the United States, where he is held over accusations of supporting .

Trump to visit Federal Reserve headquarters as feud with its chair continues

WASHINGTON (AP) — President Donald Trump is visiting the Federal Reserve headquarters in Washington Thursday, a week after indicating that Fed chair Jerome Powell's on two Fed buildings could be grounds for firing.

What's inside Elon's building in Memphis will shock you - Ad

Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the September 1st funding window closes.

Why Spotify's Latest Results Look Worse Than They Are

Spotify (SPOT) stock drops after missing earnings and revenue expectations, despite strong user growth. Analysts maintain Overweight and Buy ratings.

Trump's Bitcoin Reserve Just 'Legitimized It'—Coinbase CEO Brian Armstrong Says G20 Nations Now Rushing To Build Their Own BTC Stockpiles

Coinbase Global Inc. (NASDAQ:COIN) CEO Brian Armstrong said other G20 nations are now examining Bitcoin (CRYPTO: BTC) reserves following President Donald Trump‘s establishment of a St

Weiss Gold Veteran Makes Shocking New Call - Ad

Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold ... and reveals a little-known way to get ahead of this bull market.

Pope Leo XIV surprises Catholic youth festival with unexpected popemobile salute

VATICAN CITY (AP) — surprised tens of thousands of young Catholics on Tuesday and showed up unexpectedly at a Holy Year welcome ceremony, thrilling the kids and receiving a rock star’s welcome in the first big youth event of his pontificate.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

Monolithic Power Systems Stock Rises 4.2% After Key Trading Signal

A significant trading signal flashed for Monolithic Power Systems at a price of $778.07, after which MPWR rose up to 4.2%.

Germany halts exports of military equipment to Israel that could be used in Gaza

BERLIN (AP) — Germany won't authorize any exports of military equipment to Israel that could be used in Gaza “until further notice,” Chancellor Friedrich Merz said Friday, in a strikingly quick response by one of Israel's strongest international backers to a decision by Prime Minister Benjamin Netanyahu's Cabinet .

Investing Legend Hints the End May Be Near for These 3 Iconic Stocks - Ad

Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.

Britain's Royal Mail celebrates Monty Python with stamps featuring iconic sketches and characters

LONDON (AP) — And now for something completely different: Britain’s Royal Mail has issued stamps celebrating the absurdist comedy of .

What US consumers can expect from new tariffs on imported goods

American businesses and consumers soon will have of how President Donald Trump's foreign trade agenda might affect them now that the United States has on products from dozens of countries.

Better Than Bitcoin? (Top Crypto for Less Than $1) - Ad

Over the past 15 years, Bitcoin has outperformed stocks, bonds, and every other asset you could've bought. 2025 is already shaping up to be another banner year, with Bitcoin recently hitting a new all-time high. But there's a better way to profit from this new crypto rally. Most people don't know about it... and yet it's returned over 1,000% in 4 months. This could be the #1 way to invest in crypto right now.

Mark Cuban Says This Trump Administration Move Is 'One Of the Dumbest….'

Mark Cuban slams Commerce Dept's plan to charge patent holders a percentage of their patent value as 'dumbest idea in business history'.

Celsius Leverages Alani Nu And Zero-Sugar Trends To Capture New Market Share

Celsius's Q2 beat driven by Alani Nu integration and zero-sugar innovation sets the stage for accelerated revenue growth and EBITDA upside.

Gold Is Being Reintroduced Into the Monetary System - Ad

While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Trump administration appeals to Supreme Court to allow $783 million research-funding cuts

WASHINGTON (AP) — The Trump administration asked the on Thursday to allow it to cut hundreds of millions of dollars’ worth of research funding in its push to roll back federal diversity, equity and inclusion efforts.

No.1 Opportunity for 2025 [Take Action Now!] - Ad

Starlink's potential IPO Could Be the Biggest in History--Silicon Valley insider James Altucher has uncovered a way to profit BEFORE the IPO--with as little as $50. Musk's $180B giant is set to launch--will you miss out? Claim your spot before it's too late.

EU and Japan agree to work together to promote free trade and economic security

TOKYO (AP) — Leaders of the and Japan launched an alliance Wednesday aimed at boosting economic cooperation, defending free trade and countering unfair trade practices as the two sides face growing challenges from the United States and China.

Nissan racks up red ink, but the Japanese automaker promises a return to profit later this year

TOKYO (AP) — Japanese automaker Nissan sank into a 115.8 billion yen ($782 million) loss for April-June, but promised Wednesday to return to profitability later this year.

Trump: Don't Mess With This American Stock! - Ad

One little-known U.S. stock is 20x cheaper than AMD--yet more profitable than Airbnb, Chipotle, and Hilton. Backed by Trump and now partnering with a top AI firm, it's poised to explode.

Could Trump Accounts Turn American Babies Into Tomorrow's Millionaires? Here's What Experts Say

A new federal savings initiative, known as "Trump accounts," signed into law by President Donald Trump, could significantly alter the financial future of millions of American children. 

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright finstrategist.com
Privacy Policy | Terms of Service